Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association
CE Ndumele, J Rangaswami, SL Chow, IJ Neeland… - Circulation, 2023 - Am Heart Assoc
Cardiovascular-kidney-metabolic health reflects the interplay among metabolic risk factors,
chronic kidney disease, and the cardiovascular system and has profound impacts on …
chronic kidney disease, and the cardiovascular system and has profound impacts on …
[HTML][HTML] Heart failure with preserved ejection fraction: JACC scientific statement
The incidence and prevalence of heart failure with preserved ejection fraction (HFpEF)
continue to rise in tandem with the increasing age and burdens of obesity, sedentariness …
continue to rise in tandem with the increasing age and burdens of obesity, sedentariness …
SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism
M Packer - Nature Reviews Cardiology, 2023 - nature.com
Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce heart failure events by
direct action on the failing heart that is independent of changes in renal tubular function. In …
direct action on the failing heart that is independent of changes in renal tubular function. In …
Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention
Cardiovascular diseases (CVDs) are the leading causes of morbidity and mortality in
individuals with type 2 diabetes mellitus (T2DM). Secular changes in CVD outcomes have …
individuals with type 2 diabetes mellitus (T2DM). Secular changes in CVD outcomes have …
Ketones and the heart: metabolic principles and therapeutic implications
The ketone bodies beta-hydroxybutyrate and acetoacetate are hepatically produced
metabolites catabolized in extrahepatic organs. Ketone bodies are a critical cardiac fuel and …
metabolites catabolized in extrahepatic organs. Ketone bodies are a critical cardiac fuel and …
Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes
M Packer, CS Wilcox, JM Testani - Circulation, 2023 - Am Heart Assoc
SGLT2 (sodium-glucose cotransporter 2) inhibitors interfere with the reabsorption of glucose
and sodium in the early proximal renal tubule, but the magnitude and duration of any …
and sodium in the early proximal renal tubule, but the magnitude and duration of any …
[HTML][HTML] SGLT-2 inhibitors in heart failure: a review of current evidence
Abstract Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are the latest addition to
guideline-directed medical therapy in heart failure (HF) with reduced ejection fraction with …
guideline-directed medical therapy in heart failure (HF) with reduced ejection fraction with …
Cardiac and metabolic effects of dapagliflozin in heart failure with preserved ejection fraction: the CAMEO-DAPA trial
BA Borlaug, YNV Reddy, A Braun, H Sorimachi… - Circulation, 2023 - Am Heart Assoc
BACKGROUND: Sodium-glucose cotransporter-2 inhibitors reduce risk of hospitalization for
heart failure in patients who have heart failure with preserved ejection fraction (HFpEF), but …
heart failure in patients who have heart failure with preserved ejection fraction (HFpEF), but …
[HTML][HTML] Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes …
Due to their cardiovascular protective effect, glucagon-like peptide-1 receptor agonists (GLP-
1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) represent breakthrough …
1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) represent breakthrough …
Metabolic communication by SGLT2 inhibition
BACKGROUND: SGLT2 (sodium-glucose cotransporter 2) inhibitors (SGLT2i) can protect
the kidneys and heart, but the underlying mechanism remains poorly understood …
the kidneys and heart, but the underlying mechanism remains poorly understood …